Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents

por Kishta, Sara Sobhy, Kishta, Sobhy Ahmed, El-Shenawy, Reem
Publicado 2017

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

por Kishta, Sara, Tabll, Ashraf, Omanovic Kolaric, Tea, Smolic, Robert, Smolic, Martina
Publicado 2020